Siemens Presents Intelligent Diagnostic Solutions at AACC 2022

At AACC 2022, Siemens is holding live demonstrations of its Atellica Solution comprising flexible, scalable, automation-ready immunoassay and chemistry analyzers with integrated automation in 6m2. This includes its Atellica Integrated Automation (AIA) on the Atellica Solution that consolidates revolutionary sample management technology, intelligent software, and IT to provide workflow efficiency with the flexibility to add decapping with little or no additional footprint. Siemens will also demonstrate its automation solutions that are fully scalable, innovative, and customized for workflow for labs of all sizes. This includes its Aptio Automation solution which combines intelligent technologies with Siemens’ workflow expertise to deliver flexible solutions that advance laboratory productivity. Siemens is also demonstrating Atellica Task Targeted Automation that can drive open, one-touch sample preparation for multidisciplinary labs and Atellica Integrated Automation that can streamline a lab’s biggest chemistry and immunoassay workloads.

Siemens is also displaying its portfolio of chronic disease management solutions that provides fast, reliable, and accurate results at the point of care. This includes the Atellica DCA Analyzer for fast, quality HbA1c and ACR results at the fingertips, the CLINITEK Status Connect System with Auto-Checks Technology that simplifies and streamlines daily operations, and the POC Ecosystem Solution designed to help manage the complete POCT process across the healthcare continuum. In addition, Siemens is highlighting the Atellica 1500 Automated Urinalysis System that combines the CLINITEK Novus automated urine chemistry analyzer and the Atellica UAS 800 urine sediment analyzer in one completely automated unit.

In the field of critical care testing, Siemens is demonstrating the epoc Blood Analysis System that delivers critical testing results securely at patient-side in less than one minute. The system also connects the entire care team so it doesn’t matter if the laboratory staff and caregivers work in different parts of the hospital. Within its portfolio of innovative assays, Siemens will present the Atellica IM B·R·A·H·M·S procalcitonin assay that helps achieve early sepsis risk assessment and aids in the management of antibiotic therapy. Siemens is also highlighting the Neurofilament light chains (sNfL) assay that is intended to be used as an aid in identifying adult patients with relapsing multiple sclerosis who are at lower vs. higher risk of MS disease activity. Visitors to the Siemens AACC booth will be introduced to the Enhanced Liver Fibrosis (ELF) Test, which is the first and only biomarker to be granted FDA De Novo marketing authorization for prognosis of patients with advanced fibrosis due to non-alcoholic steatohepatitis (NASH).